BioPharmSignal logoBioPharmSignal

Biotech News

Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

AnaptysBio, Inc. (ANAB)AnaptysBio, Inc.Company update

Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026 Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their value to shareholders, as

Related news

NRIXNurix Therapeutics2026-08-04 11:00 EST

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

STTKShattuck Labs2026-06-10 04:21 EST

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

STTKShattuck Labs2026-06-09 12:00 EST

Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update

HOWLWerewolf Therapeutics2026-08-21 12:00 EST

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement

MREOMereo BioPharma2026-08-11 12:15 EST

Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

SABSSAB Biotherapeutics2026-07-30 12:30 EST

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

AnaptysBio, Inc.

Biopharma Royalty Company Following the spin-off of First Tracks Biotherapeutics, AnaptysBio manages financial collaborations rather than operating an internal drug-development portfolio. Jemperli Economics Anaptys receives royalties tied to GSK’s Jemperli franchise, including development in endometrial, rectal, colon, and head and neck...

Recent company news

ANABAnaptysBio, Inc.2026-05-12 20:15 EST

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

ANABAnaptysBio, Inc.2026-05-11 13:15 EST

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

ANABAnaptysBio, Inc.2026-05-04 20:15 EST

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

ANABAnaptysBio, Inc.2026-04-24 19:40 EST

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim

ANABAnaptysBio, Inc.2026-04-20 13:15 EST

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

Stock data

Close
57.74 USD
Market cap
1.49B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States